VIOLIN Logo
VO Banner
Search: for Help
About
Introduction
Statistics
VIOLIN News
Your VIOLIN
Register or Login
Submission
Tutorial
Vaccine & Components
Vaxquery
Vaxgen
VBLAST
Protegen
VirmugenDB
DNAVaxDB
CanVaxKB
Vaxjo
Vaxvec
Vevax
Huvax
Cov19VaxKB
Host Responses
VaximmutorDB
VIGET
Vaxafe
Vaxar
Vaxism
Vaccine Literature
VO-SciMiner
Litesearch
Vaxmesh
Vaxlert
Vaccine Design
Vaxign2
Vaxign
Community Efforts
Vaccine Ontology
ICoVax 2012
ICoVax 2013
Advisory Committee
Vaccine Society
Vaxperts
VaxPub
VaxCom
VaxLaw
VaxMedia
VaxMeet
VaxFund
VaxCareer
Data Exchange
V-Utilities
VIOLINML
Help & Documents
Publications
Documents
FAQs
Links
Acknowledgements
Disclaimer
Contact Us
UM Logo

Vaccine Detail

E. coli C4424 protein vaccine
Vaccine Information
  • Vaccine Name: E. coli C4424 protein vaccine
  • Target Pathogen: Escherichia coli
  • Target Disease: Hemorrhagic colitis
  • Vaccine Ontology ID: VO_0011442
  • Type: Subunit vaccine
  • Status: Research
  • Antigen: E. coli C4424
  • C4424 gene engineering:
    • Type: Recombinant protein preparation
    • Description:
    • Detailed Gene Information: Click Here.
  • Adjuvant:
  • Immunization Route: Subcutaneous injection
Host Response

Mouse Response

  • Host Strain: BALB/c
  • Vaccination Protocol: Purified recombinant proteins were used to immunize groups of 6-week-old BALB/c@Rj mice (Janvier Laboratories, France). Each mouse was injected subcutaneously with 20 μg of recombinant protein emulsified in complete Freund's adjuvant (Sigma) on day 1. Three weeks later (day 21), the mice were given a boosting injection with 10 μg of recombinant protein emulsified in incomplete Freund's adjuvant. A control group was included in each experiment that consisted of mice injected on days 1 and 21 with PBS and adjuvant alone (Durant et al., 2007).
  • Challenge Protocol: Control and immunized groups of mice were challenged on day 42 by intraperitoneal injection of E. coli S26 at a dose that caused death in 50% of the mouse population (LD50) (5 × 10^5 CFU/mouse). The survival of mice was monitored for 2 days after challenge. The survival rate in the vaccinated group was compared to the one obtained in the control group (Durant et al., 2007).
  • Efficacy: Active immunization of BALB/c mice with C4424 antigen in Freund's adjuvant protects mice from lethal challenge with ExPEC strain S26 (Durant et al., 2007).
References
Durant et al., 2007: Durant L, Metais A, Soulama-Mouze C, Genevard JM, Nassif X, Escaich S. Identification of candidates for a subunit vaccine against extraintestinal pathogenic Escherichia coli. Infection and immunity. 2007; 75(4); 1916-1925. [PubMed: 17145948].